biOasis Announces Publication of Scientific Paper -- Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model - Seite 2

In May, 2015, biOasis announced continued success with the Transcend Platform using its lead blood-brain barrier delivery vector, melanotransferrin peptide or MTfp, to deliver Trastuzumab (TZM) across the blood-brain barrier. The results revealed that the Transcend fusion protein MTfp-TZM showed increased activity against Her2+ brain tumors when compared to Transcend/Trastuzumab conjugates that biOasis has previously tested, including the BT2111 conjugate used in the study at Texas Tech University.

Rob Hutchison, biOasis CEO, stated, "We knew the researchers from Texas Tech University were planning to submit a paper for publication. Because it was their paper, we simply waited for the process to unfold and the wait was very much worth it. The paper has been peer-reviewed, published and has been extremely well received. The publishing of this work is very important to biOasis in order to obtain scientific acceptance in academic communities and within the pharmaceutical industry. On behalf of biOasis I want express our gratitude to all of the contributors to this very important study."

About Transcend
Transcend is biOasis' proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.